Regulus Therapeutics (RGLS) Will Present Data from Two RG-101 Abstracts in Chronic HCv
Tweet Send to a Friend
Regulus Therapeutics (Nasdaq: RGLS) announced that two abstracts related to RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 ("miR-122") for the treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
